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Background: The ‘‘Soteria paradigm’’ attempts to support
people diagnosed with schizophrenia spectrum disorders
using a minimal medication approach. Interest in this ap-
proach is growing in the United Kingdom, several European
countries, North America, and Australasia. Aims: To sum-
marize the findings from all controlled trials that have
assessed the efficacy of the Soteria paradigm for the treat-
ment of people diagnosed with schizophrenia spectrum dis-
orders.Methods: A systematic search strategy was used to
identify controlled studies (randomized, pseudorandom-
ized, and nonrandomized) employing the Soteria paradigm
to treat adults and adolescents meeting the criteria for
schizophrenia spectrum disorders according to Interna-
tional Classification of Diseases and Diagnostic and Sta-
tistical Manual for Mental Disorders criteria. Results: We
identified 3 controlled trials involving a total of 223 partic-
ipants diagnosed with first- or second-episode schizophre-
nia spectrum disorders. There were few major significant
differences between the experimental and control groups
in any of the trials across a range of outcome measures
at 2-year follow-up, though there were some benefits in spe-
cific areas. Conclusions: The studies included in this review
suggest that the Soteria paradigm yields equal, and in cer-
tain specific areas, better results in the treatment of people
diagnosed with first- or second-episode schizophrenia spec-
trum disorders (achieving this with considerably lower use
of medication) when compared with conventional, medica-
tion-based approaches. Further research is urgently re-
quired to evaluate this approach more rigorously because
it may offer an alternative treatment for people diagnosed
with schizophrenia spectrum disorders.
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In the late 1960s and early 1970s, a number of attempts
were made to create therapeutic community alternatives
to hospitalization for people diagnosed with schizophre-
nia.1,2 These tried to understand schizophrenia not as an
illness needing medical intervention but rather as an im-
portant aspect of an individual’s life history.3 Rather
than use in antipsychotic medication as a first course
of treatment, such initiatives emphasized the need to al-
low individuals to go through their experience of psycho-
sis with minimal interference and high levels of support.4
UK-based initiatives included Kingsley Hall, associated
with Laing and colleagues in the Philadelphia Associa-
tion,5 and Villa 21, associated with David Cooper.2 Per-
haps less well known is the ‘‘Soteria paradigm,’’ which
was developed by Mosher and colleagues6 in the United
States. Over the course of its 30-year history, the thera-
peutic and structural features considered specific to the
paradigm have been elucidated in some detail, with the
so-called ‘‘Soteria critical elements’’ being disseminated
to help inform the development of further Soteria proj-
ects (J. Schreiber, personal communication, Mosher,7
Mosher and Bola8). These core principles include the pro-
vision of a small, community-based therapeutic milieu
with significant lay person staffing, preservation of per-
sonal power, social networks, and communal responsibil-
ities, a ‘‘phenomenological’’ relational style which aims
to give meaning to the person’s subjective experience
of psychosis by developing an understanding of it by ‘‘be-
ing with’’ and ‘‘doing with’’ the clients, and no or low-
dose antipsychotic medication (with all psychotropic
medications being taken from a position of choice and
without coercion). Unlike many of the other alternative
approaches to the treatment of schizophrenia, the Soteria
paradigm has been subjected to quantitative empirical
enquiry via a randomized controlled methodology. Inter-
est in the Soteria paradigm has grown recently in the
United Kingdom, resulting in the formation of a national
Soteria Network, the hosting of an inaugural conference,
and discussion with regards to establishing a Soteria
House.9 Given that evaluations of the paradigm have re-
portedly been undertaken in other countries10 and that it
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is attracting renewed interest in both the United Kingdom
and other areas of the world, we decided to systematically
review the research underpinning this approach.
Aims of the Study
To evaluate the efficacy of the Soteria paradigm for per-
sons diagnosed with schizophrenia using a systematic
review of the available empirical evidence.
Methods
We searched Medline, Embase, CINAHL, Psychinfo,
and the Cochrane Library for references in all languages
using the search terms for schizophrenia and related dis-
orders specified by the Cochrane Schizophrenia Group,
together with the term ‘‘Soteria.’’ The search included all
references up to June 2005. We wrote to experts and
organizations with an interest in alternative treatment
approaches to schizophrenia and searched the references
in each article we obtained, whether included or not, for
any additional potentially relevant studies. We searched
collections by hand in the Health Sciences Library of the
University of Nottingham and the Medical Library of
Nottinghamshire Healthcare NHS Trust. The following
journals were hand-searched, in their entirety, for the pe-
riod January 1975 (the year in which the first results from
the Soteria paradigm were published) to June 2005: Acta
Psychiatrica Scandinavica, The American Journal of Psy-
chiatry, Archives of General Psychiatry, The British Jour-
nal of Psychiatry, The Journal of Nervous and Mental
Diseases, Psychological Medicine, Social Psychiatry and
Psychiatric Epidemiology, and Schizophrenia Bulletin.
These journals were selected on the basis that they
were available as complete collections for the study pe-
riod and represented the journals considered by the study
team to have the highest probability of containing articles
relating to the Soteria paradigm.
Inclusion Criteria
We included peer-reviewed evaluations of all treatment
programs calling themselves Soteria communities, affili-
ated or associated to the original Soteria community, and
adhering to the Soteria critical elements outlined above,
in accordance with current best practice guidelines for the
conduct of systematic reviews.11 We also included eval-
uations of treatment programs without the name Soteria
in their title (these studies were identified via the use of
the word Soteria in their citation or abstract) but explic-
itly modeled on the Soteria community and adhering to
the aforementioned core therapeutic principles. In an at-
tempt to ensure homogeneity with regard to the putative
therapeutic ingredients being assessed, we excluded any
studies calling themselves Soteria but not cleaving to
the Soteria critical elements. All controlled studies (ran-
domized, pseudorandomized, and nonrandomized)
assessing adults and adolescents meeting the Interna-
tional Classification of Mental and Behavioral Disorders:
International Classification of Diseases, 10th Revision12
criteria for schizophrenia, schizoptypal and delusional
disorders, or the Diagnostic and Statistical Manual for
Mental Disorders (DSM) criteria for schizophrenia spec-
trum disorders, were included. Each identified article was
independently examined to determine if it met the inclu-
sion criteria by 2 reviewers (Dr Ferriter and Dr Huband).
Details of included studies are shown in tables 1–3. Data
were extracted by the same 2 independent reviewers, with
a third reviewer (Dr Calton) adjudicating in the event of
disagreements. The decision to potentially include non-
randomized studies was taken because many systematic
reviews, including those addressing interventions for
schizophrenia, conclude that there is insufficient evidence
because too few randomized controlled trials (RCTs) have
been carried out in the area of interest.32 This may be
particularly true in areas such as minimal medication
approaches to the treatment of schizophrenia, where
conducting RCTs is likely to be considered a contentious,
or possibly inappropriate, course of action. It should also
be borne in mind that nonrandomized controlled studies
of high quality can produce outcomes that approximate
thosefoundinRCTs.33Thus,ourinclusionofnonrandom-
ized trials reflected our commitment to generating con-
structive advice for both clinicians and researchers.
Results
We identified 76 references. No language restrictions
were applied. After inspection of the full articles or trans-
lations from foreign language articles, 56 (74%) were
rejected. Table 4 shows the excluded studies and reasons
for exclusion. The remaining studies only described 3
cohorts, 2 from Soteria USA and 1 from Soteria Berne.
The paucity of data meant that it was not possible to
carry out meta-analysis or funnel plots to detect publica-
tion bias.
Description of Studies and Methodological Quality
Soteria USA: Mosher et al (1975); Mosher (1976);
Mosher and Menn (1975); Mosher and Menn (1977);
Mosher and Menn (1978); Mosher and Menn (1982);
Mathews et al (1979); Mosher (1991); Mosher et al
(1995); Mosher (1999); Bola (1999) Bola and Mosher
(2002a); Bola and Mosher (2003); Reference
Nos.13–25 These studies include data on 2 cohorts of
patients admitted to Soteria between 1971–1976 and
1976–1979 and compared patients admitted to control
group patients admitted to hospital. Bola and Mosher25
is the most recent and principal source of data. The
authors’ main claim is better 2-year outcome for patients
admitted to Soteria compared with hospital patients.
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There are a number of problems with this portfolio of
articles, some of which are explicable in terms of research
practice at the time the studies were carried out but others
less so. The data are not always presented clearly. The
first cohort was allocated to Soteria or control group
by alternate admission and today we would describe
this as pseudorandomization. The second cohort was de-
scribed as randomized though the method of randomiza-
tion is not described. We reproduce their main results
table, combining both cohorts, with significant effects
Table 1. Studies Included in This Review
Study Design
Description of
Treatment Program Control
Soteria USA (2 cohorts):
Mosher et al13; Mosher14;
Mosher and Menn15; Mosher
and Menn16; Mosher and
Menn17; Mosher and Menn18;
Mathews et al19; Mosher 20;
Mosher et al21; Mosher22;
Bola23
Bola and Mosher24;
Bola and Mosher.25
Cohort 1: quasi-experimental
design, consecutive assignment
to treatment or control arm.
Soteria project, USA General hospital inpatient
psychiatric units
Cohort 2: randomized
controlled trial
Soteria Bern: Ciompi et al10;
Ciompi26; Ciompi and
Bernascomi27; Ciompi et al28;
Ciompi et al29;
Randomization constrained
by bed availability
Soteria Berne,
Switzerland
Patients not admitted to
Soteria because there were no
vacancies
Table 2. Study Characteristics
Study Inclusion Criteria Exclusion Criteria Sample Size Outcomes
Soteria USA (2 cohorts):
Mosher et al13; Mosher14;
Mosher and Menn15;
Mosher and Menn16;
Mosher and Menn17;
Mosher and Menn18;
Mathews et al19; Mosher 20;
Mosher et al21; Mosher22;
Bola23 Bola and Mosher24;
Bola and Mosher.25
DSM-II criteria for
schizophrenia.
Not reported Cohort 1: 79 2-y follow-up:
1. Readmission to 24 h care.
2. Number of readmissions
3. Days in readmission
Deemed in need of
hospitalization
4. Global psychopathology
scale (Mosher et al30)
4 of 7 Bleulerian diagnostic
symptoms.
5. Global improvement scale
(Mosher et al30)
Not more than 1 previous
hospitalization for 30 d or less.
Cohort 2: 100 6. Living independently with
peers.
Age: 15–32 7. Ordinal measure of working
Marital status: single 8. Functioning subscale of the
Brief Follow-up Rating
(Sokis 31)
Soteria Bern: Ciompi et al10;
Ciompi26; Ciompi and
Bernascomi27; Ciompi
et al28; Ciompi et al29;
Age 17–35 Drug or
alcohol
dependency
Treatment: 22 2-y follow-up:
1. Brief Psychiatric Rating
Scale
2. Housing situation
3. Job situation
4. Global outcome, 1, 2, and 3
combined
5. Global autonomy
DSM-III-R criteria for
schizophrenia or
schizophreniform psychosis.
6. Relapse rate
At least 2 of 6 symptoms over
previous 4 weeks (delusion,
hallucinations, though
disorder, catatonia,
schizophrenic disorders of
affect, severely deviant social
behavior)
Not compliant
with treatment
Control: 22 7. Average medication dose
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reported at the conventional P < .05 level, and marginal
effects (reported at theP< .10 level in the original article)
shown as not significant. The results are shown for com-
pleting participants with data up to the 2-year follow-up
(N = 129) and endpoint analysis, which included addi-
tional data on participants who had not completed to
the end of follow-up (N = 160) where last observations
were used. There were 179 participants admitted to
the combined studies and data from the 19 drop-
outs were not included. They also include results for
completers adjusted for attrition bias but we are not
sufficiently familiar with their statistical method to com-
ment on it. There was also no sample size calculation,
and it would be useful to carry out a retrospective sample
Table 3. Results and Conclusions
Study Results Author’s Conclusions
Soteria USA (2 cohorts):
Mosher et al13; Mosher14;
Mosher and Menn15;
Mosher and Menn16;
Mosher and Menn17;
Mosher and Menn18;
Mathews et al19; Mosher 20;
Mosher et al21; Mosher22;
Bola23 Bola and Mosher24;
Bola and Mosher.25
Marginal effects of experimental treatment on 2-y
outcomes (30 comparisons)
‘‘Soteria treatment resulted in
better two-year outcomes for
patients with newly
diagnosed
schizophrenia spectrum
psychoses .’’
Endpoint N = 160
Completers N = 129
Completers adjusted for attrition bias N = 129
Composite outcome
Endpoint NS
Completers NS
Completers adjusted for attrition bias <0.05
Social functioning
Endpoint NS
Completers NS
Completers adjusted for attrition bias NS
Global psychopathology
Endpoint NS
Completers <0.05
Completers adjusted for attrition bias <0.05
Improved psychopathology
Endpoint NS
Completers NS
Completers adjusted for attrition bias NS
Working any
Endpoint NS
Completers NS
Completers adjusted for attrition bias NS
Working full time
Endpoint NS
Completers NS
Completers adjusted for attrition bias NS
Living alone or with peers
Endpoint <0.05
Completers NS
Completers adjusted for attrition bias NS
Readmission
Endpoint NS
Completers NS
Completers adjusted for attrition bias <0.05
Number of readmissions
Endpoint NS
Completers NS
Completers adjusted for attrition bias NS
Days in readmission
Endpoint NS
Completers NS
Completers adjusted for attrition bias NS
Soteria Bern: Ciompi et al10;
Ciompi26; Ciompi and
Bernascomi27; Ciompi
et al28; Ciompi et al29;
Only 2 outcomes showed significant differences between
the 2 groups: mean daily dose of medication (P < .01)
and total dose of medication (P < .05)—(9 comparisons)
‘‘The two-year outcome
revealed no significant
differences between Soteria
patients and controls ..’’
Note: NS, not significant.
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size calculation to see if the combined studies are ade-
quately powered.
At first sight, having reinterpreted the data, the results
look relatively unimpressive. Only one outcome—living
alone or with peers—showed a significant difference us-
ing endpoint analysis. Only one outcome, global psycho-
pathology, was significant based on completer data.
Three outcomes—composite outcome, global psychopa-
thology, and number of readmissions—were significant
for completers after adjusting for attrition bias.
Soteria Berne: Ciompi et al (1992); Ciompi (1997);
Ciompi and Bernascomi (1986); Ciompi et al (1991);
Ciompi et al (1993); Ciompi and Hoffman (2004);
ReferenceNos.10,26–34,88 This was a small study wherein
2-year outcome comparisons were made between 22
people diagnosed with schizophrenia or schizophreni-
form disorder using DSM-III-R criteria, and an equal
number of control cases matched on age, sex, education,
psychopathology, and duration since onset. Allocation
was by randomization constrained by bed availability,
which the authors concede may have resulted in biases.
They found significant differences only for mean daily
dose and total dose between the 2 groups, replicating
the limited differences found in the American studies.
Full details of all included studies are shown in tables
1–3 below.
Discussion
Both the research in the United States and Switzerland
showed only modest differences between the Soteria par-
adigm and standard treatment, with only 5 of the Soteria
USA, and 2 of the Soteria Berne comparisons attaining
Table 4. Excluded Articles
Study Reason for exclusion
Ahern and Fisher34 Description of the PACE philosophya
Ahern and Fisher35 Description of the PACE philosophya
Bola and Mosher36 Commentb
Bola et al37 Book chapterb
Carpenter and
Buchanan38
Commentb
Chamberlin39 Obituarya
Ciompi40 Reviewb
Ciompi41 General discussion articleb
Dauwalder42 Book chapterb
De Crescente43 Obituarya
Delaney44 Reviewb
Fabre45 General discussion articleb
Gosden46 General discussion articleb
Greenblatt and
Budson47
Edited symposiumb
Guazzeli et al48 A review of outcomes in an
experimental community in Italy for
the mentally ill. It was not clear that
all the critical elements of the Soteria
model were present. Also no control
group.b
Harangozo49 On the future direction of psychiatry in
Hungarya
Hirschfeld et al50 Participants were staff not patients.
Comparative study of personality
characteristics of staff at Soteria and
2 traditional mental health programsb
Johnson51 Book reviewa
Mazzola52 Not about the Soteria modela
Mosher et al53 Study is of psychological
characteristics of staff working at
Soteriab
Menn and Mosher54 Book chapterb
Mosher and Menn55 Book chapterb
Mosher and Menn56 Book chapterb
Mosher and Menn57 Book chapterb
Mosher and Menn58 Book chapterb
Mosher and Menn59 Book chapterb
Mosher60 General discussion articleb
Mosher and Menn61 Book chapterb
Mosher62 Book chapterb
Mosher and Hendrix63 Obituarya
Mosher et al64 Reportb
Mosher and Burti65 Book chapterb
Mosher66 Book chapterb
Mosher67 Book chapterb
Mosher and Bola68 Book chapterb
Mosher and Bola69 General discussion articleb
Mosher70 Book chapterb
Mosher71 Book chapterb
Mosher7 Book chapterb
Mosher72 Book chapterb
Mosher and Bola8 Discussion of therapeutic ingredients
within Soteria paradigmb
Peltzer and
Machleidt73
Description and limited data
improvement rates of traditional
African healing centers. No
comparator groupa
Scharfetter74 General discussion articleb
Schneider et al75 Bookb
Table 4. Continued
Study Reason for exclusion
Sharfstein76 Editorialb
Smith77 General discussion articleb
Thomas78 General discussion articleb
Wendt79 Book chapterb
Wilson80 Book chapterb
Wilson81 Book chapterb
Wilson82 Bookb
Wilson83 Book chapterb
Wilson84 General discussion article
Windgasssen and Tolle85 Commentb
Zapotoczky and Wenzel86Bookb
Ciompi et al87 Bookb
Note: PACE, Personal Assistance in Community Existence.
aThe cited article did not refer to the Soteria paradigm.
bThe cited article, although referring to the Soteria paradigm,
was either not peer reviewed or did not contain any new data
relevant to an evaluation of efficacy, or both.
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significance at the .05 level. However, in the case of the
American experiments, the direction of effects for the
remaining comparisons, while not reaching statistical
significance, did favor the Soteria treatment.23 This is
an important, though subtle, finding because in a truly
ineffective treatment (ie, no differences between the inter-
vention and control), one would expect an equal number
of comparisons to favor each treatment. Hence, the evi-
dence does not appear to indicate that the Soteria para-
digm was ineffective; rather it suggests that it seemed to
be at least as effective as traditional hospital-based treat-
ment, with this being achieved without the use of antipsy-
chotic medication as the primary treatment.
Limitations
Critical to the success of our search strategy was the con-
cept of the Soteria paradigm, ie, the existence of a thera-
peutic regimen with ingredients sufficiently specific to
demarcate said project from other minimal medication
approaches to the treatment of schizophrenia. The sem-
inal review by Bola89 of medication-free research in early-
episode schizophrenia briefly outlines the components of
the different treatments used by 8 minimal medication
comparative studies (including those cleaving to the Sote-
ria paradigm covered by the present study). We interpret
Bola as appearing to suggest that there were specific dif-
ferences with regard to the constituents of the nonmedi-
cation intervention treatments between the 2 studies
cleaving to the Soteria paradigm, and the remaining stud-
ies, thereby implying that the Soteria paradigm is specif-
ically different, in terms of its constituent features
(though not necessarily its effects) from all other minimal
medication approaches to the treatment of early-episode
schizophrenia. This, together with the existence of the
Soteria critical elements supports our assertion that the
Soteria paradigm constitutes a specific treatment format,
though this issue may be open to further debate. Despite
this we may have inadvertently included studies wherein
the term Soteria was used in an unrelated sense, or where
some, but not all, of the Soteria critical elements were in-
corporated into traditional general psychiatric hospital
wards; a problem that has been discussed elsewhere.90
Our inclusion criteria were designed to circumvent this
problem by filtering out said anomalies (with 2 of the
former and 4 of the latter being among the excluded
articles). Hence, it is likely that our review encompasses
only those peer-reviewed, controlled studies that have
assessed the efficacy of the Soteria paradigm proper.
The exclusion of data derived from books and book
contributions from our review could conceivably have
resulted in our omitting information relating to the prob-
lems of medication, qualitative aspects, and possible
explanations for the therapeutic effects of the Soteria
paradigm. However, the explicit aim of this systematic
review was to assess the best possible empirical evidence
relating to the evaluation of the efficacy of the Soteria
paradigm as a therapeutic intervention, hence our a priori
inclusion criteria. With this in mind, we focused on peer-
reviewed comparative efficacy studies, but as an addi-
tional, though a posteriori, quality assurance check, we
scrutinized all the relevant excluded book contributions.
We were unable to identify any further efficacy data in
addition to that already included in the review.
Despite a relatively large body of published literature,
there was only a very modest amount of data. It is note-
worthy that the same data from the American project
were published several times in different journals,
though, in fairness, the authors did not attempt to con-
ceal their previous publications. The quality of the re-
search was variable, with some lapses excusable within
the context of the era when the projects were carried
out (pseudorandomization), and others less so (statistical
presentation). Soteria USA included both first- and sec-
ond-episode patients, while Soteria Berne included only
individuals experiencing their first episode of schizophre-
nia. Hence, any conclusions regarding the efficacy or oth-
erwise of the Soteria paradigm may only be applicable to
those people diagnosed with early-onset schizophrenia
and cannot necessarily be applied to people diagnosed
with longer term forms of the disorder.
In addition, the American study employed DSM-II91
criteria to diagnose schizophrenia, while Soteria Berne
used DSM-III-R. The primary change from DSM-II to
DSM-III (and hence DSM-IV) was the addition of the
6-month length of symptom criterion, thus, in the era
of DSM-IV, the validity and generalizability of the find-
ings should be questioned. However, rediagnosis of the
American cohort, using DSM-IV criteria, showed that
although 58% of those individuals diagnosed with
schizophrenia at study inception were subsequently
rediagnosed with schizophreniform disorder, 68% of
these were rehospitalized within the 2-year follow-up pe-
riod and would likely have met DSM-IV criteria for
schizophrenia.24 This finding actually serves to increase
the validity of the results, given that the 6-month
DSM-IV duration criterion is particularly conservative.
There was also a paucity of economic data, though Sote-
ria USA was described as slightly cheaper, and Soteria
Berne as initially more expensive, than standard treat-
ment. However, a subsequent economic reevaluation of
Soteria Berne revealed that, by transferring social and vo-
cational rehabilitation to specialized local community-
based settings (rather than providing same within the
project itself), the project could be run at 10%–20% lower
costs than comparable local units.88
The Wider Context
These limitations notwithstanding the data do, neverthe-
less, suggest that, despite the absence of evidence for any
wide-ranging advantages for the Soteria paradigm over
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standard treatment, there are a number of compelling
reasons to reconsider the Soteria paradigm in the context
of the changing landscape of mental health services and
policy. For example, it is interesting to compare the
results from the Soteria paradigm with those from the in-
ternational studies of schizophrenia conducted by the
World Health Organization92,93 which demonstrated su-
perior outcomes for individuals diagnosed with the dis-
order in developing countries. Although a truly
compelling explanation for this finding is still awaited,
it must be remembered that the authors of the original
report concluded that differences in sociocultural factors
had the greatest explanatory power for the differences in
outcome for schizophrenia between the developing and
developed worlds.93 Taken at, albeit speculative, face
value, the Soteria paradigm seems more likely than stan-
dard treatment to approximate the supportive and collec-
tivist sociocultural mechanisms often suggested as
responsible for better developing country outcomes.25
The Question of Medication
Conventional medical treatment of people diagnosed
with schizophrenia continues to rely almost entirely on
the (sometimes involuntarily) use of antipsychotic med-
ication. The Soteria paradigm is noteworthy in that,
while not adopting a dogmatically ‘‘antimedication’’ po-
sition, it seeks to marginalize the use of medication and
treat it as something to be taken voluntarily from a posi-
tion of informed choice, without the overt or tacit com-
pulsion encountered in standard treatment settings. In
the original study,13 only 24% of the experimental group
received any medication during the initial 6 weeks of
treatment (as opposed to 100% of the hospitalized control
group), with only 16% of these receiving ‘‘substantial’’
drug treatment, ie, > 7 days.71 At 2-year follow-up,
the percentage of experimental subjects who had taken
antipsychotic medication had risen to 57%, as opposed
to 97% of the control group.25 At Soteria Berne, 73%
of the experimental group had taken antipsychotics at
two-year follow-up, compared with 95% of controls,
and the total 2-year doses of antipsychotics were 56%
lower in the experimental group.88
Such an approach clearly risks garnering oppro-
brium, given that there is a wealth of quantitative empiri-
cal evidence, suggesting that antipsychotic medication
produces statistically significant improvements in
schizophrenia symptoms,94 prevents relapse,95 and obvi-
ates the problems of a long duration of untreated psycho-
sis (DUP)96 (though, some have argued that an aversion
to engaging with conventional, medication-oriented psy-
chiatric services actually prolongs DUP97). However, the
consistency of these research results and the nature and
sustainability of longer-term outcomes have been ques-
tioned.98,99 For example, the relapse rate among patients
with a diagnosis of schizophrenia on medication remains
high and noncompliance with treatment is frequently
seen as a problem.100 In addition, some people do not re-
spond to antipsychotic medication at all,72 and research
has suggested that the only real advantage of the atypical
antipsychotics, compared with first-generation antipsy-
chotics, is the reduced risk of extrapyramidal symptoms
such as Parkinsonism, acute dystonia, and akathisia,101
though even these ‘‘negative benefits’’ have been chal-
lenged in recent years.102,103 Indeed, recent research con-
tinues to point to high levels of morbidity and lower life
expectancy for people taking atypical antipsychotic med-
ication on a long-term basis,104 with this risk operating
via an increased incidence of fatal cardiac arrhythmias
and obesity.105
Service users themselves have questioned the overreli-
ance on medication.106 They have complained that other
side effects, which are not obviated by atypical antipsy-
chotics, such as loss of motivation, sexual dysfunction,
weight gain,96 drowsiness, and restlessness108 are actually
more troubling for them than the extrapyramidal
effects.107 Partly because of these concerns, there has
been ongoing interest in creating alternatives to tradi-
tional inpatient treatment with medication.108–110 For
all these reasons, it is important to investigate the option
of therapeutic alternatives, particularly given the rise of
notions of patients or consumer ‘‘choice’’ and the grow-
ing interest in advanced directives as ways to increase pa-
tient choice and autonomy in periods of acute mental
health crisis when capacity may be hindered.111–113
Choice and Capacity in the United Kingdom
Patient choice sits at the center of current UK govern-
mental health reforms,114 has been cited as a vital com-
ponent of an evidence-based and patient-centered mental
health care system,115–117 and is also an important com-
ponent of the influential medical risk-benefit framework
for evaluating competing interventions.118 The current
National Institute for Clinical Excellence guidelines for
the management of schizophrenia state that ‘‘during an
acute episode, antipsychotic drugs are necessary,’’(p11)
a mandate not extended to psychological interventions.
Patient choice in this context is reduced to having
some say over which antipsychotic is prescribed. The
concept of choice underpins informed consent, in that
consent can only be said to be informed if a person
appreciates that there are other choices available to
them. It is interesting to consider how the concept of in-
formed consent sits within a system that treats of one
intervention as mandatory and all other treatment
modalities as inherently subsidiary.
Good practice also dictates that doctors should work
on the presumption that every adult has the capacity to
decide whether to consent to, or refuse, proposed medical
intervention, unless it is shown that they cannot under-
stand information presented in a clear way.119 Yet the
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Mental Health Act 1983 in England and Wales attributes
little significance to the patient’s capacity to consent,
a state of affairs replicated in the, now defunct, Draft
Mental Health Bill. In the context of involuntary deten-
tion perhaps absence of capacity is presumed, but this
may not be justifiable: past research has suggested that
approximately 75% of people diagnosed with schizophre-
nia understand information and make decisions similar
to comparison groups around issues of consent.120
More recent work, employing a global assessment of ca-
pacity, showed that 56% of patients admitted to an acute
general adult psychiatric ward retained treatment-related
decisional capacity,121 with mania and the presence of
delusions, not involuntary detention, being the best pre-
dictors of incapacity. Although syndromal diagnoses
were not generated, making it very difficult to draw con-
clusions about specific diagnostic categories, this suggests
that, at the very least, the majority of people admitted to
general adult psychiatric wards may retain treatment-
related decisional capacity.122 In theory, these individuals
could make an informed choice regarding their treatment
preference, yet at the present time, the only universally
accessible treatment option is medication, with or with-
out psychosocial interventions as circumstances dictate.
Future Research and Ethical Considerations
The Soteria paradigm remains an intriguing example of
medical parsimony in the treatment of schizophrenia, via
its use of significant numbers of nonmedically indoctri-
nated staff and minimal use of medication. The studies
included in this review suggest that the Soteria paradigm
yields equal (and in certain specific areas, better) results
in the treatment of schizophrenia when compared with
conventional, medication-based approaches. This review
complements the results of the meta-analysis by Bola90
which showed a small to medium, statistically nonsignif-
icant long-term advantage for the Soteria paradigm over
conventional treatment. How exactly these effects are
achieved remains moot, though explanatory models
have focused on the importance of a consistent, emotion-
ally relaxing therapeutic environment,89 a hypothesis
given strong empirical support by extant research on out-
come in schizophrenia.123,124 Importantly, the Soteria
paradigm appears to achieve its effects using consider-
ably less antipsychotic medication and at a lower overall
cost.
Other researchers have minimized the use of antipsy-
chotic medication within more orthodox medical regi-
mens employing intensive psychotherapeutically
oriented support.125–127 These studies have, like the Sote-
ria paradigm, found few advantages, yet no disadvan-
tages, for people adhering to their minimal medication
regimens. Hence, there appears to be some, albeit limited,
evidence supporting the minimal medication approach
adopted within the Soteria paradigm. However, none
of these studies adopted a rigorous randomized con-
trolled methodology. Although the evidence used to sup-
port evidence-based patient choice should arguably be
based as much as possible on systematic reviews of
RCTs, the results of observational studies, including
qualitative research, should also be given due weight
and influence.117 The paucity of RCT data for the Soteria
paradigm and the other minimal medication approaches
outlined above can only be ameliorated by further re-
search employing rigorous trial methodologies, in-depth
qualitative research utilizing user-centered outcomes,
and long-term follow-up to evaluate the paradigm’s lon-
gitudinal effects. It would also be important to give due
consideration to appropriate subgroup analyses in order
to try and identify those people (eg, those diagnosed with
true schizophreniform disorder), who might garner par-
ticular benefit from the paradigm. This, of course, can
only happen if further Soteria or Soteria-like projects
are established: such research would necessitate the use
of medication-free, or minimal medication protocols,
a potential cause for concern, but one which has been ex-
tensively debated.89,128–133 The current consensus would
appear to be that such research is not associated with
widespread problems of informed consent or adverse
consequences to patients and is ethically justifiable in
the search to identify new treatments.128
Conclusion
The lack of both quantity and quality of the evidence base
to date mean that we cannot yet recommend the Soteria
paradigm as a standard treatment. However, there is also
an absence of evidence that the regimen did harm, and
indeed, evidence to suggest specific advantages for the
paradigm over conventional treatment (with particular
regard to antipsychotic load and overall cost). In the
somewhat convoluted mantra of evidence-based medi-
cine ‘‘an absence of evidence is not evidence of an absence
of effect,’’ and it must be said that many treatments, in-
cluding the formal psychotherapies for psychosis, also
lack a substantial evidence base. Recent research has
again indicated that service users highly value the absence
of side effects134,135 and the vast majority of service users
and providers support the idea of residential crisis serv-
ices as an alternative to acute inpatient treatment.136 This
suggests that the minimal medication approach offered
by the Soteria paradigm may be more responsive to
patients’ priorities.
In terms of formal research evidence, the Soteria par-
adigm remains very much what it has always been, an in-
triguing, but in many ways still experimental approach to
the treatment of people diagnosed with schizophrenia.
However, the paradigm has been in existence for over
30 years, and it appears that there is a wealth of clinical
experience in its implementation which is at present
only available to a small number of people in a handful
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of European countries.88 Further research using more
rigorous quantitative and qualitative methodologies is
urgently required to help clarify its effects, both positive
and negative, over both the short and longer term. Given
that interest in this approach is growing internationally,
perhaps the time for this reassessment is approaching.
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